Moreover, MUC4 expression in cancer specimens would help select the subgroup of HER2-positive breast cancer patients that benefit from the combination of anti-TNFα therapies with the standard treatments, as we previously demonstrated in HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.